Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

July 05, 2016   |   News

European Commission approves opicapone – a novel treatment for Parkinson´s disease patients with motor fluctuations

Porto, 5th July 2016 - BIAL announced today that the medicinal product ONGENTYS® (opicapone) for the treatment of adult Parkinson´s disease patients with motor fluctuations was approved by the European Commission. BIAL will make opicapone available for Parkinson´s disease patients during 2016 and 2017 across Europe.

Opicapone is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

We are very pleased to achieve this major regulatory milestone for opicapone, which offers patients living with Parkinson´s disease an effective, once-daily, adjunctive treatment option. We have been developing opicapone for many years and this approval is a landmark in BIAL’s ongoing commitment to the quality of life of patients and their caregivers. This approval strengthens our track record of bringing new medicines to market,” said António Portela, CEO of BIAL.